However, this observation needs further confirmation because this therapy was not randomized, and patients at higher risk for bleeding or with a lower platelet count are less likely to receive heparin prophylaxis.
In multivariable analysis, use of bleeding avoidance strategies was associated with a lower risk of bleeding.
In our series, MICPB is associated with decreased postoperative bleeding but not with a lower transfusion rate.
In light of published reports describing a lower incidence of bleeding with continuation of warfarin than with HBT [ 11, 12] and the anticoagulants is not risk factor of post endoscopic surgery bleeding [ 26], the bleeding risk of HBT requires reassessment.
Although there is considered to be a lower risk of bleeding with D110, [ 5, 6] in our series, the majority of patients with hemorrhagic complications were taking this dose.
In the only published randomised study comparing prolonged LMWH treatment with conventional anticoagulation, the risk of bleeding with 3 months of LMWH treatment was lower than with warfarin therapy in patients with deep vein thrombosis (Pini et al, 1994).
51 The results indicated that, in patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke and systemic thromboembolism, caused less bleeding, and was associated with a lower mortality rate.
We found that illness severity and higher aPTT on the day prior to bleeding onset were independently associated with bleeding, while anticoagulant administration on the day prior was associated with a lower risk of bleeding.
Others have observed a progressive increase in both minor and major bleeding events with lower levels of kidney function for patients during hospitalization for ACS [ 28] or in the course of follow up thereafter while on antiplatelet therapies [ 17, 18, 27].
Anticoagulation underuse was not inferior in patients with a lower bleeding risk and/or a higher stroke risk and underuse was surprisingly not inferior either in the AF patients who had previously had a stroke.
